CTS™ immune cell SR for serum free culture and expansion of human T cells

Background The manufacture of a majority of clinical T cell products for immunotherapy applications requires in vitro T cell culture and expansion. Commercialization of T cell manufacturing processes requires reagents that meet regulatory guidelines and ultimately help reduce manufacturing cost of goods. A key component in many T cell culture protocols is human serum, which is expensive and requires extensive testing prior to use for the manufacture of cGMP-compliant T cell therapies. To this end, we have developed a xeno-free serum replacement, CTSTM Immune Cell SR, with defined components that can be used in combination with multiple cell culture media to support in vitro expansion of functionally intact T cells.